This Nano-Cap Pharma Stock Surged 80% Days After A Listing Warning — What’s Fueling the Rally?

• The funding includes a $10.5 million upfront offering and up to $20.9 million from warrant exercises.
• The company plans to use the proceeds to advance new protein and peptide research programs.
• Last week, Azitra received a notice from the NYSE for failing to meet its minimum stockholders’ equity requirement of $6 million.

Shares of Azitra Inc. (AZTR) surged more than 80% on Friday, crossing over its 100-day moving average for the first time since June 2025, after the biopharmaceutical firm announced a private placement to raise over $31 million.

Source: TradingView

On Friday, AZTR shares recorded their biggest intraday gains since July 27, 2024.

Azitra To Advance New Protein And Peptide Research Programs

Azitra said it is in the process of securing a financing deal worth up to $31.4 million to support its expansion into the cosmetic and cosmeceutical markets. The funding includes an initial $10.5 million offering through convertible preferred stock, with an additional $20.9 million tied to the potential exercise of warrants.

The transaction is backed by institutional healthcare investors, including Stonepine Capital and Nantahala Capital.

The company plans to use the proceeds to advance new protein and peptide research programs, using its microbial genetic engineering platform. Azitra aims to accelerate the development and commercialization of skincare solutions targeting issues such as dry skin and ageing.

“We are confident these technologies offer an exciting new way to address the appearance of fine lines and wrinkles as well as dry, sensitive skin and eczema-like rashes,” said CFO Francisco Salva.

Azitra’s Listing Challenges

Last week, Azitra received a notice from NYSE American LLC for failing to meet its minimum stockholders’ equity requirement of $6 million for companies with recent losses. The company has until April 1, 2027, to regain compliance, during which it will remain listed but will be subjected to regular reviews of its progress.

According to Azitra’s latest financial update for the full-year ended Dec. 31, 2025, net loss widened to $11 million from $9 million a year earlier.

The company also said it expects to report the topline Phase 1b results for its lead candidate, ATR12-351, for the treatment of Netherton, a rare and severe genetic skin disorder, in the second half of 2026.

How Did Stocktwits Users React?

Despite the intraday surge, retail sentiment has remained in the ‘bearish’ zone over the past 24 hours.

One user said the stock could climb over $1 on the daily chart if the volume holds.

Nearly 230 million shares changed hands in the first 20 minutes of trading, compared with an average of 1.8 million, according to Stocktwits data.

Year-to-date, the stock has gained around 23%.

Read also: AAPL Stock’s Decline Leads It Toward 200-DMA For First Time In Over 7 Months – Retail Concerned Over Lack Of Catalysts

For updates and corrections, email newsroom[at]stocktwits[dot]com.